Bank of New York Mellon Corp Reduces Stake in Anika Therapeutics, Inc. (NASDAQ:ANIK)

Bank of New York Mellon Corp trimmed its stake in shares of Anika Therapeutics, Inc. (NASDAQ:ANIKFree Report) by 56.1% during the 3rd quarter, Holdings Channel.com reports. The fund owned 61,098 shares of the biotechnology company’s stock after selling 77,984 shares during the quarter. Bank of New York Mellon Corp’s holdings in Anika Therapeutics were worth $1,138,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of ANIK. Tower Research Capital LLC TRC grew its position in Anika Therapeutics by 61.2% during the 3rd quarter. Tower Research Capital LLC TRC now owns 1,601 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 608 shares during the last quarter. Altshuler Shaham Ltd bought a new position in Anika Therapeutics during the 4th quarter worth approximately $58,000. Teachers Retirement System of The State of Kentucky purchased a new stake in Anika Therapeutics in the 3rd quarter worth approximately $84,000. SG Americas Securities LLC purchased a new stake in Anika Therapeutics in the 3rd quarter worth approximately $124,000. Finally, UBS Group AG lifted its holdings in Anika Therapeutics by 16.6% in the 3rd quarter. UBS Group AG now owns 5,781 shares of the biotechnology company’s stock worth $137,000 after buying an additional 825 shares during the period. 90.79% of the stock is currently owned by institutional investors.

Anika Therapeutics Stock Performance

NASDAQ ANIK opened at $23.66 on Friday. Anika Therapeutics, Inc. has a fifty-two week low of $16.54 and a fifty-two week high of $32.33. The stock has a 50 day simple moving average of $22.83 and a two-hundred day simple moving average of $20.74. The stock has a market cap of $346.38 million, a P/E ratio of -14.00 and a beta of 0.73.

Wall Street Analysts Forecast Growth

Separately, Barrington Research increased their price objective on Anika Therapeutics from $28.00 to $29.00 and gave the stock an “outperform” rating in a report on Wednesday, January 3rd.

View Our Latest Report on Anika Therapeutics

Anika Therapeutics Profile

(Free Report)

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and bone preserving joint solutions in the United States, Europe, and internationally.

See Also

Want to see what other hedge funds are holding ANIK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anika Therapeutics, Inc. (NASDAQ:ANIKFree Report).

Institutional Ownership by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.